Every Form 4 that CME Group Inc. (CME) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CME and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CME filings page.
CME Group Inc. Chief Transformation Officer Ken Vroman reported an open-market sale of Class A common stock. On March 12, 2026, he sold 5,160 shares at a weighted average price of $309.00 per share, with individual trade prices ranging from $308.969 to $309.11. Following this transaction, he directly holds 14,910 CME Group Class A common shares.
CME Group Inc. director Elizabeth A. Cook reported an indirect open-market sale of 1,000 shares of Class A common stock held by a trust on March 6, 2026, at $320 per share. After this transaction, the trust’s indirect holdings totaled 17,771 CME Group shares.
CME Group Inc. director Bryan T. Durkin reported an open-market sale of Class A common stock. On February 23, 2026, he sold 4,200 shares at a weighted average price of $309.65 per share, within a price range of $309.25 to $310.07. After this transaction, he directly holds 43,007 shares of CME Group Class A common stock.
CME Group Inc. director Martin J. Gepsman reported an open-market sale of Class A common stock. He sold 300 shares at a price of $305.90 per share. After this sale, he directly owns 24,999 shares of CME Group Class A common stock.
CME Group Inc. director Dennis Suskind reported selling 748 shares of Class A common stock on February 6, 2026 at a price of $300 per share. After this transaction, he beneficially owned 2,699 shares of CME Group common stock in direct ownership.
CME Group Inc. reported that its Chairman and CEO Terrence A. Duffy, who is also a director, sold 25,000 shares of Class A common stock on December 11, 2025.
The sale was executed in two trades: 13,809 shares at prices ranging from $268.66 to $269.66 per share and 11,911 shares at prices ranging from $269.68 to $270.51 per share, with prices within each $1 range aggregated and reported on a weighted-average basis. After these transactions, Duffy directly beneficially owned 65,804 Class A shares.
CME Group Inc. officer Derek Louis Sammann, Senior Managing Director and Global Head of Commodities Markets, reported several transactions in CME Class A common stock. On November 6, 2025, he transferred 2,300 shares at a stated price of $0, reducing his direct holdings to 8,683 shares and increasing the holdings of his revocable living trust to 16,914 shares, reflecting an internal ownership reorganization.
On November 20, 2025, the trust sold 5,886 shares at $275.65 per share, leaving the trust with 11,028 shares. On the same date, Sammann’s spouse sold 1,314 shares at $275.74 per share, leaving 7,022 shares held by the spouse. These trades update disclosed indirect ownership positions through both the trust and spouse.
CME Group (CME) insider transaction: Officer Hilda Harris Piell, Sr MD & Chief HR Officer, reported a Code G gift of 973 Class A common shares on 11/07/2025 at a reported price of $0. Following the transaction, she beneficially owns 29,418 shares, held directly.
The filing notes the shares were gifted to her donor advised fund. This is a charitable transfer rather than a market sale.
CME Group Inc. (CME) reported an insider transaction: Director Harold Ford Jr. sold 1,000 Class A shares on November 3, 2025, coded S (open market sale). The weighted average sale price was $263.53, with a price range of $263.21–$263.68.
Following the sale, he directly owns 1,091 shares. The company notes prices within a $1 range were aggregated and maintains detailed records available upon request.